Virginia Deal
Adult Health · Hickory, NCNPI 1548402670
Payments from drug & device makers
Across 85 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$274
- AbbVie$162
- Bristol Myers Squibb$151
- Merck$132
- AstraZeneca$124
- Novartis$110
- plus $696 from 17 others
What the payments were for
- Food & beverage$1,51492%
- Education$1348%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $274 |
| AbbVie | 9 | $162 |
| Bristol Myers Squibb | 8 | $151 |
| Merck | 6 | $132 |
| AstraZeneca | 7 | $124 |
| Novartis | 5 | $110 |
| GSK | 5 | $109 |
| Incyte Corporation | 1 | $100 |
| Astellas Pharma US Inc | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Array Biopharma Inc | 3 | $54 |
| Inari Medical, Inc. | 3 | $45 |
| Mirati Therapeutics, Inc. | 2 | $41 |
| Biocon Biologics Inc | 1 | $31 |
| Epizyme, Inc. | 2 | $30 |
| Tempus AI, Inc | 1 | $30 |
| Accord Healthcare, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $20 |
| Pfizer | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Acceleron Pharma, Inc. | 1 | $11 |
How this compares
$1,648 in reported general payments places this provider in the 75th percentile of 614 adult health providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 79 | $1,104,925 |
| CabometyxCabozantinib S-Malate | 25 | $624,563 |
| JakafiRuxolitinib Phosphate | 30 | $457,307 |
| CalquenceAcalabrutinib Maleate | 26 | $374,023 |
| RevlimidLenalidomide | 23 | $373,619 |
| BrukinsaZanubrutinib | 25 | $351,729 |
| IbrancePalbociclib | 22 | $349,501 |
| Lenalidomide | 25 | $347,757 |
| ImbruvicaIbrutinib | 22 | $330,565 |
| TagrissoOsimertinib Mesylate | 14 | $230,506 |
| VenclextaVenetoclax | 28 | $177,904 |
| Abiraterone Acetate | 30 | $149,709 |
| NubeqaDarolutamide | 15 | $134,796 |
| EliquisApixaban | 190 | $130,350 |
| OrgovyxRelugolix | 21 | $55,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $74 | $1,104,92579 claims |
| AstraZenecaCalquence, Tagrisso | $124 | $604,52940 claims |
| PfizerIbrance, Eliquis | $13 | $479,851212 claims |
| Incyte CorporationJakafi | $100 | $457,30730 claims |
| Bristol Myers SquibbRevlimid | $151 | $373,61923 claims |
| AbbVieVenclexta, Creon | $162 | $189,77840 claims |
| Johnson & JohnsonXarelto | $274 | $10,19111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 adult health providers in North Carolina.
Other adult health in Hickory
- Diane Erickson-FoxHickory$14K
- Amanda RepassHickory$12K
- Rae PalmerHickory$8K
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.